share_log

Oppenheimer Maintains Outperform on Cellectar Biosciences, Lowers Price Target to $12

Benzinga ·  Nov 19, 2024 21:22  · Ratings

Oppenheimer analyst Jeff Jones maintains Cellectar Biosciences (NASDAQ:CLRB) with a Outperform and lowers the price target from $14 to $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment